Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Pfizer Inc.

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting

May 25, 2023

From Pfizer Inc.

Via Business Wire

Pfizer’s PAXLOVID™ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19

May 25, 2023

From Pfizer Inc.

Via Business Wire

FDA Advisory Committee Votes in Support of Approval for Pfizer’s Vaccine Candidate to Help Prevent RSV in Infants Through Maternal Immunization

May 18, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Prices $31,000,000,000 Debt Offering

May 16, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Announces Proposed Notes Offering

May 15, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Reports First-Quarter 2023 Results

May 02, 2023

From Pfizer Inc.

Via Business Wire

U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children

April 27, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Declares Second-Quarter 2023 Dividend

April 26, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27

April 13, 2023

From Pfizer Inc.

Via Business Wire

FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI

April 04, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts

March 21, 2023

From Pfizer Inc.

Via Business Wire

FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™

March 16, 2023

From Pfizer Inc.

Via Business Wire

Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval

March 10, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults

February 28, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

February 27, 2023

From Pfizer Inc.

Via Business Wire

Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance

February 22, 2023

From Pfizer Inc.

Via Business Wire

U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review

February 21, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study

February 16, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults

February 16, 2023

From Pfizer Inc.

Via Business Wire

FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib)

February 10, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

February 09, 2023

From Pfizer Inc.

Via Business Wire

PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE

January 31, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries

January 17, 2023

From Pfizer Inc.

Via Business Wire

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children

January 06, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

January 03, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate

December 29, 2022

From Pfizer Inc.

Via Business Wire

U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents

December 28, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis

December 21, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of January 31 Conference Call with Analysts

December 20, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial

December 10, 2022

From Pfizer Inc.

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.